Thank you, Mark. I'll start with revenue. Our total revenue from continuing operations for the third quarter was $22.5 million compared to the prior year of $12 million. Revenue from the Service segment was $12.4 million compared to just $2.9 million in the prior year. That's an increase of $9.5 million or 332%. This increase was a direct result of the increased project work in the segment, primarily from contracts awarded in the past few quarters. Revenue from our Treatment segment was $10.1 million compared to $9.1 million in the prior year, an increase of $978,000 or 10.7%. This increase was primarily from average higher -- higher average pricing from waste process and disposed. For 9 months ending September 30, our total revenue is $51.4 million compared to $37.8 million in the prior year. Both of our service -- both of our segments' revenues have increased compared with prior year with the Service segment increasing by 101% from increased project work, while the Treatment segment revenue is up 10.6% from that average higher pricing. Our cost of sales was $17.4 million compared to $10.2 million in the prior year. Cost in the Treatment segment decreased $796,000 as a result of a decrease in the closure expenses at our M&EC facility of $1.1 million last year. The decrease was offset by increases in our variable costs, which relates to revenue. While our fixed facility costs remained relatively flat. In our Service segment cost of sales increased by $8 million as a result of the increase in revenue. Our gross profit for the quarter was $5.2 million compared to $1.8 million in the third quarter of 2018. That's an increase of $3.3 million or 182.6%. Excluding the $1.1 million reduction in closure expenses at M&EC, gross profit increased by $2.2 million or 76.7%. Gross profits were higher -- were impacted by higher revenue in both segments as fixed costs increased only marginally in the Service segment, despite the significant increase in revenue. Our year-to-date gross profit sits at $10.9 million compared to $7.2 million last year. This increase is the result of higher revenue in both segments and the reduction of closure expenses at M&EC offset by higher fixed costs. Our SG&A for the quarter was $2.9 million or 13% of revenue, up from $2.6 million or 22% of revenue last year, and this is due to higher labor-related expenses. Year-to-date, our SG&A were $8.5 million or 60.6% of revenue compared to $8.1 million or 21.3% of revenue in '18. Higher payroll-related and property expense were the main drivers for this increase. Our income from continuing operations net of taxes for the quarter was $1.9 million compared to $317,000 in -- last year, excuse me. Year-to-date income from continuing operations was $1.7 million compared to $1.4 million in the prior year. We had a net income attributable to common shareholders for the quarter of $1.8 million compared to last year's net income of $221,000. Year-to-date, income attributable to common shareholders was $1.4 million compared to $965,000 last year. We had basic and diluted net income per share for the quarter of $0.15 compared to net income per share of $0.02 in the prior year. On a year-to-date basis, basic net income per share was $0.12 compared to $0.08 in prior year, and diluted net income per share was $0.11 compared to $0.08 in the prior year. Our adjusted EBITDA from continuing operations for the quarter, as we defined in this morning's press release, was $2.4 million compared to $510,000 last year. And our year-to-date adjusted EBITDA from continuing operations is $3.5 million compared to $2.1 million in the prior year. Turning to some key balance sheet activity compared to 12/31/18. Our cash on the balance sheet was $2.4 million compared to $810,000 at year-end. Cash from the Finite Risks fund and the operating -- the improved operating performance were the main drivers for that improvement. Our accounts receivable and unbilled receivables collectively have increased by $9.2 million reflecting the increased activity in the service segment. Our current assets are up $710,000 due to higher prepaid expenses, primarily from the renewal of the company's insurance program. Our operating lease right-of-use assets were $2.6 million, representing the present value of operating leases as a result of implementing the new ASC 842 lease regulations. Intangible and other assets were $4.5 million, primarily from the release of the $5 million -- were down $4.5 million, primarily from the release of the $5 million of the Finite Risks sinking fund and the closure of the M&EC facility. Our current liabilities from continuing operations were up $4 million, primarily due to increases in the Services segment. Backlog at quarter end was $10.6 million, down from 11.1% at year-end, but up from the $9.4 million at September 2018. Our long-term liabilities from continuing operations were up $3.3 million, primarily from the new accounting for leases under ASC 842, of which, $2.4 million of the increase represents the present value of our operating lease liability. Our total debt at quarter end was $5 million, excluding debt issuance costs, of which, $2 million is owed to PNC Bank, $2.3 million to our shareholder loan and $670,000 for other financing debt. Next, I'll summarize our year-to-date cash flow activity in September of 30 of '19. Cash used for continuing operations was $3 million. Cash used for discontinued operations was $459,000. Cash used for investing in continuing operations, primarily capital, was $812,000. Cash provided from investing activities from discontinued operations was $100,000. Cash provided from financing was $1.1 million, and this is made up of our monthly payments to our term loan of $717,000, net payments to our revolver of $639,000, $2.3 million from funds received from the shareholder loan, net of repayments made and other lease financing of $119,000. Finally, before I turn the call over to questions, I'd like to take the opportunity to discuss the fixed cost savings in the Treatment segment that resulted from the M&EC closure. At the time the decision was made in 2016 to close M&EC, we anticipated that this would result in a decrease of fixed facility expenses between $4 million, $5 million. The noncash reductions in depreciation and amortization accounted for about $2.4 million of this amount, while the other fixed costs included labor -- including labor represented the cash savings. The cash savings portion turned out to be approximately $1.9 million for a total fixed cost reduction of $4.3 million. The facility is now closed, and we are not incurring costs at this location. So the $4.3 million savings have been realized. However, since the announcement, which was over 3 years ago, the segment has evolved and there's been strategic changes and other changes that have increased in other operating expenses. In 2016, Treatment revenue was $32.5 million and this year, 2019, we're annualized estimate trending at about $40 million. About $5 million of this increase has come from new business that was not at M&EC. In order to generate this new revenue, we've incurred additional labor and of course cost of living increases that have increased payroll by about $1.5 million. And the other big number that's gone up has been the health care cost, which have increased about $400,000. In addition, the costs -- certain costs have been incurred at M&EC through June of '19 this year, and there've been a few other unusual costs, which annualize at about $1 million. These should not recur moving forward. So in summary, our fixed cost of goods sold in 2016 were approximately $19.5 million. 3 years later, our third quarter annualized run rate of these fixed costs are $17.5 million. That comes from a decrease of $4-plus million at M&EC, which is partly offset by the $2 million of new -- of costs from new business and inflationary related increase. With that, operator, I'll now turn the call over to questions.